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Abstract
Purpose—Incessant ovulation has been consistently linked to epithelial ovarian cancer (EOC). 
Although reproductive characteristics differ substantially by race, the association between 
incessant ovulation and EOC has been evaluated only in populations of predominantly white 
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women. In the present study, we examined the association between lifetime number of ovulatory 
cycles (LOCs) and EOC risk among African American (AA) women.
Methods—We used data from 534 cases and 722 controls enrolled in the African American 
Cancer Epidemiology Study (AACES). LOCs were determined using the standard method, with 
modifications to include episodes of irregular or missed periods. Multivariable logistic regression 
was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association 
between LOCs and EOC risk overall and by age, while adjusting for appropriate confounders.
Results—The mean number of LOCs was 378.2 ± 105.8 for cases and 346.4 ± 117.3 for 
controls. Women in the highest tertile of LOCs had a 59% higher odds of EOC compared to 
women in the lowest tertile (OR=1.59; 95% CI=1.15–2.20). When examining this relationship by 
age, the positive association with EOC was stronger among women <50 years of age (OR for 
highest vs. lowest tertile=2.61; 95% CI=1.15–5.94), followed by women aged 50–60 years 
(OR=2.27; 95% CI=1.30–3.94). Yet, no association was present among women aged >60 years 
(OR=0.79; 95% CI=0.45–1.40).
Conclusions—In a population of AA women, we observed a positive association between LOCs 
and EOC risk, providing further support for the hypothesis that incessant ovulation contributes to 
the etiology of EOC.
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INTRODUCTION
One of the leading hypotheses for epithelial ovarian cancer (EOC) development is incessant 
ovulation.[1, 2] The causal mechanism as to how the ovulatory process contributes to 
carcinogenesis is unknown, yet several theories have been proposed. During ovulation, the 
ovarian surface epithelium is damaged and then repaired through extensive cellular 
proliferation, increasing genomic instability and the likelihood of spontaneous errors during 
DNA replication.[3] Gonadotropin and steroid hormone exposure during ovulation is 
suspected to facilitate transformation, either directly or indirectly through estrogen.[4, 5] 
Ovulation is also linked to inflammation, which is now considered a hallmark of all cancers.
[6] During ovulation, many inflammatory mediators, such as cytokines and prostaglandins, 
are elevated and may enhance mutagenesis.[7] The incessant ovulation hypothesis is 
supported by the consistent positive association between the lifetime number of ovulatory 
years or cycles and EOC risk in the literature.[8–13] In addition, risk reduction for EOC has 
been observed for reproductive factors that interrupt ovulation (e.g., pregnancy, use of oral 
contraceptives, and breastfeeding).[8, 14–16] It is also important to note that the 
reproductive characteristics used to calculate LOCs may impact ovarian cancer risk through 
additional mechanisms, independent of ovulation suppression. [17, 18]
The majority of the literature examining the relationship between incessant ovulation and 
EOC risk has been in study populations of primarily white women. However, there are 
considerable differences in reproductive characteristics by race that may impact the 
distribution of lifetime number of ovulatory cycles (LOC) and potentially its relationship to 
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EOC risk. In comparison to white women, African American (AA) women are more likely 
to have a greater number of pregnancies [19], which would result in fewer ovulations. Also, 
AA women are less likely to use oral contraceptives and breastfeed [19] and typically have 
an earlier age at menarche [20], which would contribute to a greater number of ovulations. 
To date, no studies have evaluated the association between LOCs and ovarian cancer risk 
among AA women. Therefore, we used the largest case-control study of EOC in AA 
women, the African American Cancer Epidemiology Study (AACES), to examine the 
relationship between LOCs and the risk of EOC in AA women.
METHODS
Study Population
AACES is a population-based case-control study of self-identified AA women with incident 
invasive EOC in 11 geographic locations in the United States (Alabama, Georgia, Illinois, 
Louisiana, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Tennessee, and 
Texas). The methods for AACES have been previously described.[21] In brief, cases were 
identified through rapid case ascertainment at cancer registries, hospitals, and gynecologic 
oncology clinics. The eligibility criteria for cases included women who self-identified as AA 
race, were 20–79 years of age, and were diagnosed with incident EOC between December 1, 
2010 and December 31, 2015. Random digit dialing was used to identify controls, who were 
frequency-matched to cases by geographic location and 5-year age categories. Controls were 
excluded if they had a previous diagnosis of EOC, did not have an intact ovary, and 
identified as a race other than AA. Participants completed a baseline survey by telephone 
that included detailed questions on demographic characteristics, reproductive and medical 
history, exogenous hormone use, personal and family history of cancer, and lifestyle 
behaviors (e.g., smoking, physical activity). A shortened version of this questionnaire was 
given to participants who may have otherwise refused. In total, 602 cases and 752 controls 
were enrolled in AACES, with 71 women completing the short version of the questionnaire 
(52 cases and 19 controls). The response rate was 40% for cases and 52% for controls, and 
the cooperation rate was 62% for cases and 68% for controls. [21]
Assignment of Menopausal Status and Age at Menopause
Given the complex nature of determining menopausal status and the age at menopause, we 
developed an algorithm that utilized self-reported menstrual history to assign menopausal 
status and age at menopause, while considering menopausal symptoms, premenopausal 
hysterectomy, and menopausal hormone use. Women were considered premenopausal if they 
reported that their periods were still occurring naturally and had an intact uterus at the time 
of diagnosis/interview, and perimenopausal if they reported that their periods were still 
occurring but sometimes noticed skipped months or noticed changes in their cycle. Women 
were considered postmenopausal if they reported that their periods stopped naturally or 
stopped due to chemotherapy or radiation. Women who were taking menopausal hormones 
before their periods stopped were considered perimenopausal if they had taken menopausal 
hormones for less than two years or postmenopausal if they had taken hormones for more 
than 2 years. Women who reported a premenopausal hysterectomy without bilateral 
oophorectomy were considered premenopausal if they did not report any menopausal 
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symptoms and were aged 47 or younger, and women were considered perimenopausal if 
they did not report any menopausal symptoms and were between the ages of 47 and 50, or if 
they reported menopausal symptoms for less than 2 years and were younger than 50 years at 
diagnosis/interview. Otherwise, women who had a premenopausal hysterectomy were 
considered post-menopausal if they were over 50 at the time of diagnosis/interview (age at 
menopause was estimated as 50 years) or if they were younger than 50 at the time of 
diagnosis/interview and reported menopausal symptoms for more than 2 years (age at 
menopause was estimated as the minimum of the age when 2 years of menopausal 
symptoms had been experienced and age 55).
Lifetime Number of Ovulatory Cycles
The number of ovulatory cycles was calculated using the standard method in the Cancer and 
Steroid Hormone (CASH) Study [9, 13], with modifications to account for periods of 
amenorrhea as suggested by Moorman, et al.[11] To calculate the total number of ovulatory 
years, we subtracted the age at menarche from the age at menopause for postmenopausal 
women or the reference age for pre or perimenopausal women (age at diagnosis for cases 
and age at interview for controls). The number of ovulatory years was then reduced by 
months of pregnancy, oral contraceptive use, breastfeeding, and episodes of irregular or 
missed periods. We then multiplied the total number of ovulatory years by an average cycle 
length of 28.1 days (13 cycles per year) to estimate the total number of ovulatory cycles. The 
total number of LOCs was divided into tertiles based on the distribution of LOCs in the 
controls to create categories of low (≤304), medium (305–410), and high LOCs (≥411).
Statistical Analysis
Detailed breastfeeding data was only available in the long version of the AACES 
questionnaire and therefore, we excluded women who completed the short questionnaire 
from the analyses. A total sample of 534 cases and 722 controls with complete data on all 
reproductive characteristics and covariates were included in the analyses for the present 
study. The distribution of LOCs and each component of the LOC calculation (e.g., months of 
pregnancy, oral contraceptive use, breastfeeding, periods of amenorrhea) were estimated 
overall and by case-control status. Multivariable logistic regression was used to estimate 
odds ratios (ORs) and 95% confidence intervals (CIs) for the association between LOCs and 
EOC risk, overall and by age (<50 years, 50–60 years, and >60 years). All models were 
adjusted for the study design variables, age (years) and study site (Alabama, Georgia, 
Illinois, Louisiana, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Tennessee, 
and Texas). We also present results where we additionally adjusted for several well-
established and suspected risk factors for ovarian cancer, including: family history of ovarian 
or breast cancer in a first-degree relative (yes, no); tubal ligation that occurred at least 1 year 
prior to the diagnosis date for cases or the interview date for controls (yes, no); 
premenopausal hysterectomy that occurred at least 1 year prior to the diagnosis date for 
cases or the interview date for controls (yes, no), body powder exposure (any genital use, 
only nongenital use, never use); smoking (never, former, current smokers); body mass index 
(BMI; normal weight or BMI <25 kg/m2, overweight or BMI 25–29.9 kg/m2, obese or ≥30 
kg/m2); endometriosis (yes, no); pelvic inflammatory disease (PID; yes, no); any 
recreational physical activity 1 year prior to the diagnosis date for cases or the interview date 
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for controls (yes, no); and any non-steroidal anti-inflammatory drug (NSAID) use (yes, no). 
Body powder exposure is defined as any use of talc, cornstarch, baby, or deodorizing 
powders at least one time per month for a duration of at least 6 months [22], and NSAID use 
is defined as the use of aspirin or non-aspirin NSAIDs at least once a week or at least 5 days 
out of the month for a duration of 6 months or longer. [23] Given the high correlation of 
LOCs with age, we also evaluated whether higher-order terms for age (e.g., age2 and age3) 
should be included in the regression models; however, these polynomial terms did not 
improve model fit and were not included in subsequent analyses. Given that EOC is a 
heterogeneous disease, we also repeated these analyses stratified by histology. Serous and 
endometrioid EOC were each evaluated separately, but due to the low prevalence of 
mucinous, clear cell, mixed and other epithelial histologic sub-types in AACES, we did not 
have adequate power to evaluate each separately and instead, grouped them together in an 
‘other histology’ category.
RESULTS
The distribution of AACES participant characteristics overall and by case-control status are 
provided in Table 1. As expected, cases were significantly more likely to have a family 
history of breast or ovarian cancer, endometriosis, pelvic inflammatory disease, and any 
genital use of body powders, and cases were less likely to have a history of tubal ligation. 
The majority of cases were diagnosed with serous EOC (71%), had more late stage disease 
(64% Stage 3–4), and had high grade tumors (67% Grade 3–4).
Reproductive events are provided in Table 2 by case-control status and age. In the total 
population, the mean number of ovulatory cycles was 359.9 ± 113.6. A significantly higher 
number of LOCs was observed among cases compared to controls (378.2 ± 105.8 and 346.4 
± 117.3, respectively). When evaluating the components of the LOC individually, we 
observed that controls had a greater mean number of months spent pregnant, using oral 
contraceptives, breastfeeding, and missed or irregular cycles. There were virtually no 
differences in age at menarche between cases and controls; however, cases had a slightly 
higher mean age at last period compared to controls (47.6 years and 46.3 years, 
respectively). There was also a considerable difference in the mean time between menarche 
and the last period between cases (351.0 months) and controls (322.5 months). When 
examining reproductive events by age, we observed that the mean number of LOCs 
increased as age increased. However, a significant difference in the number of LOCs by 
case-control status was only observed among women aged 60 or younger. Among women 
aged <50 years, cases were significantly more likely to have an older age at last period and a 
greater number of months between menarche and last period, and cases were significantly 
less likely to have a greater number of months spent pregnant as well as breastfeeding. 
Similar results were observed among women aged 50–60 years, with cases significantly 
more likely to have a greater number of months between menarche and last period, yet less 
months of oral contraceptive use and breastfeeding. No significant differences in 
reproductive events were observed among women older than 60 years of age.
Table 3 provides the estimated ORs and 95% CIs for the relationship between LOCs and 
EOC risk overall and by age (<50 years, 50–60 years, >60 years). Overall, in the fully 
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adjusted model, women in the highest tertile of LOCs had a 59% greater odds of EOC 
compared to women in the lowest tertile of LOCs (OR=1.59; 95% CI=1.15–2.20). When 
examining this relationship by age, the positive association with EOC risk was more 
pronounced among women younger than 50 years of age, irrespective of LOC category. The 
highest risk was observed among women younger than 50 years who had a high number of 
LOCs (OR=2.61; 95% CI=1.15–5.94). Among women aged 50–60 years, a positive 
association was still present among women who had a high number of LOCs, OR=2.27 
(95% CI=1.30–3.94), although less pronounced. Yet, no association was observed in women 
older than 60 years of age for any tertile of LOCs.
Histologic subtype-specific analyses are presented in Table 4. Among serous EOC, medium 
and high numbers of LOCs were associated with a significantly increased EOC risk after 
adjustment for confounding (Medium: OR=1.56; 95% CI=1.08–2.25 and High: OR=1.73; 
95% CI=1.19–2.52). When restricting to intermediate and high-grade serous EOC (grade 2–
4), a slightly more pronounced association is observed, OR comparing high to low tertile of 
LOCs=1.76; 95% CI=1.18–2.63 (data not shown). A more pronounced association was 
observed among women with endometrioid EOC, where over a 2-fold increased risk was 
present for the high category of LOCs (OR=2.83; 95% CI=1.26–6.40). No association was 
observed among the other histologic subtypes.
DISCUSSION
In a population of AA women, we observed a significant increase in EOC risk as the lifetime 
number of ovulatory cycles increased. This association was more pronounced among women 
younger than 50 years of age, yet no association was present among women older than 60 
years. There were also marked differences by histology, with a stronger association present 
for women with endometrioid EOC and a significant positive association still present among 
serous EOC.
Our findings suggested that the association between LOCs and EOC risk was strongest 
among women younger than 50 years of age, which is consistent with several studies that 
evaluated this association by age or menopausal status and noted a more pronounced 
association among younger or premenopausal women, and a null or slightly positive, but not 
statistically significant, association among older or postmenopausal women.[10, 12, 24] 
Similarly, a reduced effect of oral contraceptive use, a component of the LOC calculation, on 
ovarian cancer risk has been observed among older women.[24–26] The stronger effects 
among younger women could be due to several suspected factors. First, it could be due to a 
latency effect. As with most cancers, there is a relatively long time period between disease 
initiation and clinical detection.[27] It may be that excess ovulations occurring at younger 
ages are the most influential in initiation of ovarian cancer, conferring a more pronounced 
risk in the group of women younger than 50 years of age in the present study. Additionally, 
as women age, there are considerable fluctuations in hormone levels associated with 
ovulation. Gonadotropin levels increase with age, yet estradiol levels are relatively stable 
until menopause, where they significantly decline.[28] Given that estrogen may mediate 
ovulation [4, 5], reduced estradiol levels at older ages may contribute to the reduced effect 
observed in older women. Temporal differences in reproductive characteristics may also 
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contribute to the differences in effect by age. For example, older birth cohorts tended to have 
larger families and used oral contraceptives more frequently than younger birth cohorts.[29] 
This would result in a reduced number of ovulatory cycles for older birth cohorts, and may 
manifest as a reduced effect on EOC risk among older women. Lastly, a stronger LOC and 
EOC risk association was observed among endometrioid tumors, which typically occur at 
younger ages than serous tumors. This is evident in AACES where the mean age of 
endometrioid cases was approximately 4 years younger than serous cases (54.8 years and 
58.6 years, respectively).
We observed a more pronounced association among endometrioid EOC cases, yet a 
significant positive association was still present among serous EOC cases. Unfortunately, 
due to small numbers of other non-serous EOC cases diagnosed in AACES, we had 
inadequate power to evaluate each of the other non-serous subtypes separately. In three other 
studies that examined histologic-specific results [8, 10, 12], the most pronounced magnitude 
of effect was observed in clear cell, endometrioid, and other epithelial EOC; however, a 
significant positive association was also present among serous EOC. In a manuscript by 
Schildkraut, et al. [9], a more pronounced association between lifetime number of LOCs and 
EOC risk was observed among cases with p53 mutations. We now know that a high 
frequency of p53 mutations are observed in high-grade serous EOC cases, while in the other 
histologic subtypes of EOC, there are virtually no p53 mutations present.[30] This suggests 
that the result of a more pronounced association among cases with p53 mutations in 
Schildkraut, et al. [9] may be reflective of serous EOC, and would be consistent with our 
findings by histologic subtype. However, a subsequent study by Webb, et al.[31] did not 
replicate the findings by Schildkraut, et al. [9] and instead, observed no association between 
LOCs and EOC risk among cases with p53 mutations. It is also important to note that the 
pathology review to confirm diagnosis and histology is still ongoing in AACES, which may 
result in misclassification by histologic subtype. However, histologic subtype was changed 
for less than 10% of the cases that have undergone pathology review and it is unlikely that 
misclassification by histologic subtype will have an impact on our results.
In an attempt to evaluate how our findings differ from those observed in other races, we 
compared our findings to those presented in Moorman, et al. [11], where data from a 
population of predominately white women was used for the analyses and a similar algorithm 
was used to calculate LOCs as in the present study. In Moorman, et al. [11], the mean 
number of LOCs among cases was 325.6 and 305.6 among controls, while in our study, the 
mean number of LOCs was slightly more elevated, 378.2 in cases and 346.4 in controls. It 
appears that the number of LOCs in AA women may be higher than in white women; 
however, these differences in LOCs could also be due to the differences in algorithms used 
in each study as well as the considerable differences in the number of missed or irregular 
periods between both studies. In our study, a small proportion of women reported having 
episodes of missed or irregular periods (12%) and the average number of months of missed 
periods was 2.4 months, while in Moorman, et al. [11], the mean was much greater, at 27.6 
months. Given the heterogeneity of analytic techniques used to calculate LOCs and the 
varying distribution of race in the existing literature examining this association, it is difficult 
to make any definitive conclusions as to how our findings in AA women differ in 
comparison to other races.
Peres et al. Page 7













A limitation of studies on this topic is the inability to accurately characterize the lifetime 
number of ovulatory cycles. The calculation of LOCs is dependent on self-reported data of 
reproductive characteristics. Although recalling pregnancies and other reproductive 
exposures has been reported with good reproducibility and reliability, menstrual cycle 
characteristics, including episodes of missed periods, may be more difficult to report with 
accuracy.[32, 33] Errors in recall could impact findings if recollection of reproductive 
characteristics differed between cases and controls. However, it is unlikely that cases and 
controls would vary in their recall, and if any bias did occur, it would likely be 
nondifferential misclassification and attenuate our effect estimates. In addition, it is 
important to note that not all cycles are ovulatory and not all periods of amenorrhea are 
anovulatory [34], which may also impact misclassification errors. For women who have had 
a premenopausal hysterectomy, determination of LOCs is challenging because these women 
will continue to ovulate after surgery, but it is impossible to know for how long. In an 
attempt to accurately estimate LOCs for these women, we considered if and when 
menopausal symptoms were experienced after surgery to estimate age at menopause. To 
evaluate any effect this may have had on our results, we repeated our analyses excluding 
women who had a premenopausal hysterectomy, and no substantial differences were 
observed between these results and our overall findings. There are considerable variations in 
how LOCs are calculated across studies. A recent study by Yang, et al. [35] identified 18 
different algorithms that have been used to calculate LOCs in the literature. Irrespective of 
the differences in these algorithms, they were all highly correlated with one another. Due to 
this finding as well as the consistency of our results with previous studies, it is unlikely that 
our study is greatly affected by this potential bias.
In summary, our findings among AA women support previous research suggesting that 
incessant ovulation contributes to the etiology of ovarian cancer, especially among younger 
women. Due to the small numbers of AA women with EOC in other available datasets (e.g., 
the Black Women's Health Study, the Ovarian Cancer Association Consortium), pooling data 
on AA women from AACES and other studies will offer the best attempt at testing the 
incessant ovulation hypothesis in AA women. Future studies need to evaluate this 
relationship in racially heterogeneous populations in order to make direct comparisons by 
race-ethnicity; only then will we be able to determine whether racial differences in 
reproductive characteristics impact the distribution of LOCs and its association with EOC. It 
is also clear that further research is needed at the molecular level to understand the biologic 
mechanism with which incessant ovulation influences ovarian cancer risk and why ovulation 
may have a greater impact on cancer development among younger women.
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Table 1
Distribution of AACES participant characteristics for 534 invasive EOC cases and 722 controls (N=1,256)
Cases (n=534) Controls (n=722)
p-valuen (%) n (%)
Age at Diagnosis or Interview
 Years, Mean (SD) 57.5 (10.8) 54.9 (11.8) <0.001
Study Site
 Alabama 34 (10) 73 (10)
 Georgia 86 (16) 140 (19)
 Illinois 4 (1) 39 (5)
 Louisiana 41 (8) 58 (8)
 Michigan 39 (7) 62 (9)
 North Carolina 100 (19) 112 (16)
 New Jersey 37 (7) 57 (8)
 Ohio 31 (6) 71 (10)
 South Carolina 81 (15) 59 (8)
 Tennessee 23 (4) 0 (0)
 Texas 58 (11) 51 (7)
First Degree Family History of Breast or Ovarian Cancer
 No 389 (73) 592 (82) <0.001
 Yes 145 (27) 130 (18)
BMI (kg/m2)a
 Underweight or normal (<25) 80 (15) 135 (19) 0.22
 Overweight (25–29.9) 142 (27) 184 (24)
 Obese (≥30) 312 (58) 403 (56)
Smoking Status
 Never smoker 297 (56) 422 (58) 0.05
 Current smoker 96 (18) 150 (21)
 Former smoker 141 (26) 150 (21)
Endometriosis
 No 476 (89) 687 (95) <0.001
 Yes 58 (11) 35 (5)
Pelvic Inflammatory Disease
 No 491 (92) 685 (95) 0.04
 Yes 43 (8) 37 (5)
Body Powder Exposureb
 Never use 198 (37) 338 (47) <0.001
 Any genital use 234 (44) 245 (34)
 Only non-genital use 102 (19) 139 (19)
Any NSAID Usec
 No 340 (64) 468 (65) 0.67
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Cases (n=534) Controls (n=722)
p-valuen (%) n (%)
 Yes 194 (36) 254 (35)
Any Recreational Physical Activitya
 No 195 (37) 233 (32) 0.14
 Yes 339 (63) 489 (68)
Tubal Ligationa
 No 340 (64) 430 (60) 0.14
 Yes 194 (36) 292 (40)
Premenopausal Hysterectomya
 No 410 (77) 560 (78) 0.74
 Yes 124 (23) 162 (22)
Histologyd
 Serous 364 (71)
 Mucinous 28 (5)
 Endometrioid 60 (12)
 Clear cell 15 (3)
 Mixed 9 (2)
 Other epithelial 36 (7)
Stagee
 I 116 (24)
 II 46 (10)
 III 274 (58)
 IV 38 (8)
Gradef
 1 45 (10)
 2 104 (23)
 3 298 (66)
 4 2 (1)
AACES: African American Cancer Epidemiology Study; EOC: epithelial ovarian cancer; SD: standard deviation; BMI: body mass index; NSAID: 
non-steroidal anti-inflammatory drugs
a
1 year before diagnosis date for cases and interview date for controls.
b
Talc, cornstarch, baby, or deodorizing powder use at least one time per month for a duration of at least 6 months.
c
Aspirin and non-aspirin NSAID use at least once a week or at least 5 days out of the month for a duration of ≥6 months.
d
22 cases are missing histology.
e
60 cases are missing stage.
f
85 cases are missing grade.
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Table 3
Estimated odds ratios and 95% confidence intervals for the association between lifetime number of ovulatory 
cycles and EOC risk overall and by age
Cases Controls Model 1a Model 2b
Lifetime Ovulatory Cycles n (%) n (%) OR (95% CI) OR (95% CI)
All ages
 Low (≤304) 115 (22) 235 (33) 1.00 (Referent) 1.00 (Referent)
 Medium (305–410) 188 (35) 247 (34) 1.40 (1.03–1.91) 1.38 (1.01–1.89)
 High (≥411) 231 (43) 240 (33) 1.69 (1.23–2.32) 1.59 (1.15–2.20)
<50 years
 Low (≤304) 50 (38) 129 (59) 1.00 (Referent) 1.00 (Referent)
 Medium (305–410) 54 (41) 69 (31) 1.79 (1.01–3.16) 1.76 (0.96–3.24)
 High (≤411) 28 (21) 21 (10) 2.55 (1.18–5.52) 2.61 (1.15–5.94)
50–60 years
 Low (≤304) 29 (15) 67 (24) 1.00 (Referent) 1.00 (Referent)
 Medium (305–410) 60 (32) 105 (38) 1.35 (0.78–2.34) 1.49 (0.84–2.64)
 High (≥411) 99 (53) 106 (38) 2.25 (1.32–3.81) 2.27 (1.30–3.94)
>60 years
 Low (≤304) 36 (17) 39 (17) 1.00 (Referent) 1.00 (Referent)
 Medium (305–410) 74 (36) 73 (32) 1.01 (0.56–1.79) 0.90 (0.49–1.65)
 High (≥411) 104 (49) 113 (50) 0.93 (0.54–1.60) 0.79 (0.45–1.40)
EOC: epithelial ovarian cancer; OR: odds ratio; CI: confidence interval
a
Model 1 adjusted for the study design variables, including age and study site.
b
Model 2 is additionally adjusted for family history of breast or ovarian cancer in a first degree relative, tubal ligation, premenopausal 
hysterectomy, BMI, physical activity, smoking status, body powder exposure, any NSAID use, endometriosis, and pelvic inflammatory disease.
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Table 4
Estimated odds ratios and 95% confidence intervals for the association between lifetime number of ovulatory 
cycles and EOC risk by histology
Cases Controls Model 1a Model 2b
Lifetime Ovulatory Cycles n (%) n (%) OR (95% CI) OR (95% CI)
Serous, All ages
 Low (≤304) 68 (19) 235 (33) 1.00 (Referent) 1.00 (Referent)
 Medium (305–410) 134 (37) 247 (34) 1.60 (1.12–2.29) 1.56 (1.08–2.25)
 High (≥411) 162 (45) 240 (33) 1.85 (1.28–2.66) 1.73 (1.19–2.52)
Endometrioid, All ages
 Low (≤304) 14 (23) 235 (33) 1.00 (Referent) 1.00 (Referent)
 Medium (305–410) 10 (17) 247 (34) 0.72 (0.30–1.75) 0.64 (0.26–1.60)
 High (≥411) 36 (60) 240 (33) 3.09 (1.42–6.71) 2.84 (1.26–6.40)
Other histologyc, All ages
 Low (≤304) 25 (32) 235 (33) 1.00 (Referent) 1.00 (Referent)
 Medium (305–410) 30 (38) 247 (34) 1.05 (0.58–1.93) 0.97 (0.53–1.79)
 High (≥411) 24 (30) 240 (33) 0.88 (0.45–1.70) 0.73 (0.37–1.46)
EOC: epithelial ovarian cancer; OR: odds ratio; CI: confidence interval
a
Model 1 adjusted for the study design variables, including age and study site.
b
Model 2 is additionally adjusted for family history of breast or ovarian cancer in a first degree relative, tubal ligation, premenopausal 
hysterectomy, BMI, physical activity, smoking status, body powder exposure, any NSAID use, endometriosis, and pelvic inflammatory disease.
c
Other histology includes mucinous, clear cell, mixed and other EOC.
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